Navigating Treatment Options for Advanced Myeloproliferative Neoplasms: A Look at Azacitidine and Combination Therapies
Myeloproliferative neoplasms (MPNs) can unfortunately progress to accelerated or blast phases, presenting a critically important challenge for patients and clinicians. These advanced stages frequently enough render individuals ineligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation (allo-HCT), leaving a critical need for effective alternative strategies. Hypomethylating agents (HMAs), like azacitidine and decitabine, have emerged as important options in these scenarios, and recent research is exploring the potential benefits of combining them with targeted therapies.
While HMAs aren’t curative, they can offer valuable disease control. The question remains: can we improve outcomes further by pairing hmas with drugs like ruxolitinib (a Janus kinase inhibitor) or venetoclax (a BCL2 inhibitor)? Early studies suggested promise, with a 2020 phase 2 trial demonstrating favorable overall survival (OS) with the combination of ruxolitinib and decitabine. Though, a extensive understanding of the optimal approach requires more data.
Recently, a multi-centre analysis led by Ianotto and colleagues sought to address this knowledge gap.The study, published in Hemasphere, examined 149 patients with accelerated or blast-phase MPNs who were not candidates for more aggressive treatments. Patients received either azacitidine alone (60 patients) or in combination with other therapies (89 patients), most commonly azacitidine plus venetoclax. A subset also received azacitidine with ruxolitinib, or a combination of all three.
The study cohort had a median age of 75,reflecting the typical patient population facing these advanced MPNs.After a median follow-up of 15 months, the overall median OS was 8.04 months, with a 3-year OS rate of 13%. As expected, patients with blast-phase disease experienced significantly shorter survival (6.24 months) compared to those with accelerated-phase disease (18.0 months). Complex karyotype and TP53 mutations were also associated with poorer outcomes, highlighting the importance of risk stratification.
Interestingly, patients receiving azacitidine in combination with other agents showed a trend towards longer survival (10.08 months vs. 6.96 months),though this difference wasn’t statistically significant. This might potentially be due to a higher proportion of patients with more unfavorable disease characteristics in the monotherapy group.
However, a deeper dive into the combination therapy subgroups revealed a compelling finding. Patients treated with azacitidine and ruxolitinib demonstrated a median OS of 18.0 months – a substantial enhancement compared to 9.0 months for those receiving azacitidine plus venetoclax, and 10.08 months for the triple therapy combination (p = .015). This OS figure is particularly encouraging, exceeding results observed in previous studies.
Critically important Considerations & Future Directions
It’s crucial to acknowledge the limitations of this study. the retrospective nature and lack of randomized treatment assignment prevent definitive conclusions about the “best” treatment option. Patient heterogeneity also plays a role. However, these findings strongly suggest that the azacitidine-ruxolitinib combination warrants further examination.
This research underscores a critical need for novel therapeutic strategies, particularly for patients with high-risk features. As we continue to refine our understanding of MPN biology and treatment responses, we can strive to deliver more effective and personalized care to those facing these challenging diagnoses.
References:
- Orvain C, Tavitian S, Mediavilla C, et al. Outcome of patients with accelerated and blast-phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination-A FIM study. Hemasphere. 2025;9(9):e70202. Published 2025 Sep 4. doi:10.1002/hem3.70202
- Mascarenhas JO, rampal RK, Kosiorek HE, et al. Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase. Blood Adv. 2020;4(20):5246-
Keep reading